References
- Dunn C DR. The chemical and biological properties of busulfan (myleran). Exp Hematol 1974; 2: 101–117
- Ross W CJ. Biological Alkylating Agents. Butterworths, London 1962; 68
- Mitchell MP, Walker IG. Studies on the cytotoxicity of myleran and dimethylmyleran. Can J Biochem 1972; 50: 1074–1081
- Alexander P, Lett JT. The biological significance of the changes produced in the deoxyribonucleic acid of cells treated with radiolabeled diomimetic alkylating agents. Biochem Pharmacol 1960; 4: 34–38
- Brooks D, Lawley PD. The reaction of mono-and di-functional alkylating agents with nucleic acids. Biochem J 1961; 80: 496–503
- Peters WP, Henner WD, Grochow LB, et al. Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. Cancer Res 1987; 47: 6402–6406
- Brodsky I, Fuscaldo AA, Ehrlick BJ, et al. Analysis of platelets from patients with thrombocythemia for reverse transcriptase and viruslike particles. JNCI 1975; 55: 1069
- Strayer DR, Brodsky I, Caranfa MJ, Gillespie DH. Quantitation of RNA-dependent platelet DNA polymerase in patients with myeloproliferative disorders. Br J Haematol 1982; 50: 521–530
- Brodsky I, Strayer DR, Gillespie DH. Platelet DNA polymerase levels in CML: implications for oncogenesis. Leukemia Res 1984; 8(5)761–768
- Gillespie D, Gaspari M, Strayer DR. Addition of deoxynucleotides to an RNA primer by a DNA polymerase of human platelets. Biochem Biophys Res Commun 1981; 99: 1191
- Brodsky I, Fuscaldo AA, Ehrlick BJ, Fuscaldo KE. Effects of busulfan on oncornavirus-like activity in platelets and chromosomes in polycythemia vera and essential thrombocythemia. JNCI 1977; 59: 61
- Sarngadharan MG, Sarin PS, Reitz MS, Gallo RC. Reverse transcriptase activity of human acute leukemia cells: purification of the enzyme, response to AMV 70S RNA, and characterization of the DNA product. Nature New Biol 1972; 240: 67
- Viola MV, Frazier M, Wiernik PH, et al. Reverse transcriptase in leukocytes of leukemic patients in remission. N Engl J Med 1976; 294: 75
- Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 1981; 304: 441
- Bergsagel DE, Baily AJ, Langley R, et al. The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med 1979; 301(14)743–748
- Tucker MA, Coleman CN, Cos RS, et al. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 1988; 318(2)76–81
- Greene MH, Harris EL, Gershenson DM, et al. Melphalan may be a more potent leukemogen than cyclophosphamide. Ann Intern Med 1986; 105: 360–367
- Haanen C, Mathe G, For EORTC. Treatment of polycythemia vera by radiophosphorus or busulfan: a randomized trial. Br J Cancer 1981; 44: 75
- Brodsky I. Guest editorial-Busulfan: effect on platelet RNA dependent DNA polymerase-implications in the treatment of polycythemia vera, thrombosis and atherosclerosis. Biomedicine 1982; 36(3)125–127
- Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute non-lymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983; 309: 1347–1353
- Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 75(5)1382–1388
- Brodsky I. Speculations on the treatment and pathophysiology of polycythemia vera and chronic myelogenous leukemia. Cancer Invest 1986; 4(3)281–285
- Pederson-Bjergaard J, Ersboll J, Hansen VL, et al. Carcinoma of the urinary bladder after treatment with a cyclophosphamide for non-Hodgkin's lymphoma. N Engl J Med 1988; 318: 1028–1031